Literature DB >> 29327920

Generation of Optogenetically Modified Adenovirus Vector for Spatiotemporally Controllable Gene Therapy.

Kazuo Takayama1,2,3, Hiroyuki Mizuguchi1,3,4.   

Abstract

Gene therapy is expected to be utilized for the treatment of various diseases. However, the spatiotemporal resolution of current gene therapy technology is not high enough. In this study, we generated a new technology for spatiotemporally controllable gene therapy. We introduced optogenetic and CRISPR/Cas9 techniques into a recombinant adenovirus (Ad) vector, which is widely used in clinical trials and exhibits high gene transfer efficiency, to generate an illumination-dependent spatiotemporally controllable gene regulation system (designated the Opt/Cas-Ad system). We generated an Opt/Cas-Ad system that could regulate a potential tumor suppressor gene, and we examined the effectiveness of this system in cancer treatment using a xenograft tumor model. With the Opt/Cas-Ad system, highly selective tumor treatment could be performed by illuminating the tumor. In addition, Opt/Cas-Ad system-mediated tumor treatment could be stopped simply by turning off the light. We believe that our Opt/Cas-Ad system can enhance both the safety and effectiveness of gene therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29327920     DOI: 10.1021/acschembio.7b01058

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  4 in total

Review 1.  Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors.

Authors:  Paul Boucher; Xiaoxia Cui; David T Curiel
Journal:  J Control Release       Date:  2020-09-03       Impact factor: 9.776

2.  Session 2SFA-the symposium "Elucidation of biological functions by optical control" on BSJ2019 at Miyazaki, Japan.

Authors:  Hisao Tsukamoto; Yoshinori Shichida
Journal:  Biophys Rev       Date:  2020-02-12

3.  An Optogenetic Controllable T Cell System for Hepatocellular Carcinoma Immunotherapy.

Authors:  Bixing Zhao; Yingchao Wang; Xionghong Tan; Xiaoyuan Zheng; Fei Wang; Kun Ke; Cuilin Zhang; Naishun Liao; Yuan Dang; Yingjun Shi; Youshi Zheng; Yunzhen Gao; Qin Li; Xiaolong Liu; Jingfeng Liu
Journal:  Theranostics       Date:  2019-03-06       Impact factor: 11.556

Review 4.  CRISPR based therapeutics: a new paradigm in cancer precision medicine.

Authors:  Shehnaz Bano; Prachi Kapse; Sumit Das; Gopal C Kundu
Journal:  Mol Cancer       Date:  2022-03-25       Impact factor: 27.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.